Telesis Bio and Cellibre Announce Collaboration to Optimize Development of Future BioXp® DBC instrument
October 19 2022 - 9:00AM
Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and
synthetic biology solutions, and Cellibre, a leading manufacturing
technology company, today announced initiation of work under a
collaboration to optimize the development and validation of Telesis
Bio’s BioXp® Digital-to-Biological Converter™ (DBC) instrument
for fully automated manufacturing of on-demand CRISPR-Cas9 guide
RNA (gRNA) for genome editing.
Over the past several years, CRISPR-Cas9 gRNA technology has
emerged as a promising platform for genome editing and cellular
engineering by allowing researchers to readily alter genetic
sequences. However, rapid production of high-quality gRNA remains
challenging, resulting in significantly increased timelines during
the design-build-test cycles of discovery and development. Telesis
Bio addresses these challenges by empowering researchers with a
rapid automated solution for gRNA synthesis from a digital sequence
input, reducing the build process by a week or more and reducing
the iterative cycle time.
By integrating Telesis Bio’s short oligonucleotide ligation
assembly (SOLA) enzymatic DNA synthesis (EDS) technology directly
onto its recently released BioXp® 9600 system, the BioXp® DBC
instrument empowers scientists with same-day design and build
capabilities for their guide RNAs, and without the need to order
custom reagents. The gRNA synthesis kit is the first of several
BioXp® DBC kits the company has planned.
As part of this collaboration, Cellibre scientists will use
their proprietary technology and cell line to rapidly evaluate and
validate Telesis Bio’s emerging solutions for automated synthesis
of gRNA while using it to accelerate their cell engineering
workflows for various natural product production platforms.
“Our deep and long-standing partnership with Telesis Bio will
enhance and expand their highly automated solutions for synthetic
biology applications,” said Ben Chiarelli, CEO of Cellibre.
“Together, we can leverage our extensive experience and
capabilities in cell engineering and Telesis Bio’s leading
automation and enzymatic DNA synthesis technologies to build a
robust, on-demand solution for the rapid production of guide
RNA.”
“We believe our SOLA EDS solution is the enabling technology for
the Digital-to-Biological Converter, or DBC, and it starts with its
integration on our recently released BioXp® 9600 system,” said Todd
R. Nelson, PhD, CEO of Telesis Bio. “We look forward to working
with the Cellibre team to validate and enhance our automated BioXp®
DBC solution for generating CRISPR-Cas9 guide RNA on demand.”
About CellibreCellibre is a manufacturing
technology company that employs an organism-agnostic approach to
turn cells into specialized, sustainable factories for the
manufacture of globally significant products at scale. Cellibre's
world-class scientific team has led programs from napkin to
commercial, pioneering revolutionary breakthroughs in energy,
ingredients, medicines and more. The Company's initial strategic
focus is deploying our expertise to enable the production of
pharmaceutical-grade natural products, alleviating the need for
agriculture or ecosystem disruption entirely and revolutionizing
the way these vital ingredients are sourced, produced and
consumed.
About Telesis BioTelesis Bio is empowering
scientists with the ability to create novel, synthetic
biology-enabled solutions for many of humanity’s greatest
challenges. As inventors of the industry-standard Gibson Assembly®
method and the first commercial automated benchtop DNA and mRNA
synthesis system, Telesis Bio is enabling rapid, accurate, and
reproducible reading and writing of biology for numerous downstream
markets. The award-winning BioXp® system consolidates, automates,
and optimizes the entire synthesis, cloning, and amplification
workflow. As a result, it delivers virtually error-free synthesis
of DNA and RNA at scale within days and hours instead of weeks or
months. Scientists around the world are using the technology in
their own laboratories to accelerate the design-build-test paradigm
for novel, high-value products for precision medicine, biologics
drug discovery, vaccine and therapeutic development, genome
editing, and cell and gene therapy. Telesis Bio is a public company
based in San Diego. For more information, visit telesisbio.com.
All trademarks are the property of Telesis Bio (formerly Codex
DNA Inc.), For specific trademark information, contact us
at help@telesisbio.com.
Forward-Looking StatementsThis press release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended. Such
forward-looking statements are based on Telesis Bio’s (formerly
Codex DNA) beliefs and assumptions and on information currently
available to it on the date of this press release. Forward-looking
statements may involve known and unknown risks, uncertainties and
other factors that may cause Telesis Bio’s actual results,
performance, or achievements to be materially different from those
expressed or implied by the forward-looking statements. These and
other risks are described more fully in Telesis Bio’s filings with
the Securities and Exchange Commission (“SEC”) and other documents
that Telesis Bio subsequently files with the SEC from time to time.
Except to the extent required by law, Telesis Bio undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Media Contact:
Charlie Schmidt
Sr. Director of Marketing
charlie@codexdna.com
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Jul 2023 to Jul 2024